News for Marinus Pharmaceuticals Inc (61Y.BE)

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the "Company" or "Marinus"), a pharmaceutical company dedicated to the development of innovative therapeutics to

Marinus Pharmaceuticals, Inc. , a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it plans to release financial results... | February 10, 2021

According to Coherent Market Insights, the global epileptic seizures treatment market is estimated to be valued at US$ 3.0 billion in 2020 and is expected to exhibit a CAGR of 5.4% during the...

Shares of Marinus Pharmaceuticals, Inc. (MRNS) are climbing more than 11% Wednesday morning after the company received a positive response from the FDA that the efficacy and safety data resulting from the company's phase III study on the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder (CDD) appear sufficient to support the filing of a New Drug Application (NDA).